BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18403212)

  • 1. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
    Duan W; Peng Q; Masuda N; Ford E; Tryggestad E; Ladenheim B; Zhao M; Cadet JL; Wong J; Ross CA
    Neurobiol Dis; 2008 Jun; 30(3):312-322. PubMed ID: 18403212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
    Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
    Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
    Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
    Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
    Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
    Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
    Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
    J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effects of psychotropic drugs in Huntington's disease.
    Lauterbach EC
    Int J Mol Sci; 2013 Nov; 14(11):22558-603. PubMed ID: 24248060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
    Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
    Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.
    Aggarwal M; Duan W; Hou Z; Rakesh N; Peng Q; Ross CA; Miller MI; Mori S; Zhang J
    Neuroimage; 2012 May; 60(4):2086-95. PubMed ID: 22342677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
    Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
    J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
    Gill JS; Jamwal S; Kumar P; Deshmukh R
    Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
    Southwell AL; Ko J; Patterson PH
    J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.
    Mughal MR; Baharani A; Chigurupati S; Son TG; Chen E; Yang P; Okun E; Arumugam T; Chan SL; Mattson MP
    Hum Mol Genet; 2011 Feb; 20(4):659-69. PubMed ID: 21106706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.